Is the price fair?
What TARS's price assumes
Tarsus Pharmaceuticals, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 5.63× revenue.
5.63
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.1%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +17%
Growth the price implies · The price pays for +17% free cash flow growth a year for a decade; revenue has grown +265% a year over the last three.
- Price / book
- 8.64
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 8.64
- EV / EBIToperating margin −8.0%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 5.58
- Free cash flow, trailing twelve months
- $56M
- Market capitalisation
- $2.72B
- 3-year revenue growth
- +265%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.